A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

Macular Degeneration Clinical Trial

Official title:

Safety, Tolerability and Pharmacokinetics of Single Rising Intravitreal Doses and Multiple Intravitreal Dosing of BI 754132 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration (Open Label, Non-randomized, Uncontrolled).

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04002310
• Other study ID #: 1418-0001
• Secondary ID: 2018-004125-92
• Status: Terminated
• Phase: Phase 1
• Start date: July 26, 2019
• Est. completion date: August 9, 2022

Study information

• Verified date: September 2023
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a study in adults with geographic atrophy, an advanced form of age-related macular degeneration. The purpose of this study is to find out how well different doses of BI 754132 are tolerated. The participants are in the study for about 4 months. During this time, they visit the study site about 10 times. Participants receive 1 injection of BI 754132 directly into one of the eyes affected by geographic atrophy. In this study, BI 754132 is given to humans for the first time. The doctors compare how well participants tolerate the different doses of BI 754132. The doctors also regularly check the general health of the participants.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 18
• Est. completion date: August 9, 2022
• Est. primary completion date: August 9, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion criteria:

• Men and women with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD): For the SRD part, the GA lesion in the study eye must be = 1.9 mm2 disc area in size (approximately = 0.75 disc area in size); For the MD part the total GA lesion size in the study eye must be = 7.5 mm2 (approximately = 3 disc area in size)
• Fellow eye is not required to have GA
• Best Corrected Visual Acuity (BCVA):
• SRD part: BCVA of 20/100 to 20/400 Snellen (corresponding to 19 to 53 letters in the ETDRS chart) in the study eye equivalent measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol
• MD part: BCVA score of =53 letters (Snellen equivalent of 20/100) in the study eye
• Age = than 50 years
• Best-corrected VA in the non-study eye must have a better best-corrected VA compared to the study-eye
• Women of childbearing potential (WOCBP) cannot be included. Men able to father a child must be ready and able to use highly effective methods of birth control per International Council on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.
• Signed informed consent consistent with International Council on Harmonisation Good Clinical Practice (ICH GCP) guidelines and local legislation prior to participation in the trial, which includes medication washout and restrictions
• Not under any administrative or legal supervision or under institutionalization due to regulatory or juridical order Exclusion criteria
• GA in either eye because of causes other than AMD
• History of choroidal neovascularization (CNV) in the study eye and in the fellow eye
• Previous treatment in the study eye for GA secondary to AMD within 6 months prior to screening visit (ongoing therapy with vitamin and mineral supplements is allowed)
• Additional eye disease in the study eye that could compromise
• best corrected VA (BCVA) with visual field loss,
• uncontrolled glaucoma intraocular pressure (IOP>24),
• clinically significant diabetic maculopathy,
• history of ischemic optic neuropathy or retinal vascular occlusion,
• symptomatic vitreomacular traction,
• genetic disorders such as retinitis pigmentosa);
• history of high myopia > 8 diopters in the study eye and
• anterior segment and vitreous abnormalities in the study eye that would preclude adequate observation with Spectral Domain Optical Coherence Tomography (SD-OCT)
• Any prior intraocular surgery in the study eye other then uneventful lens replacement for cataract within 3 months prior to screening
• Aphakia or total absence of the posterior capsule. Yttrium aluminum garnet (YAG) laser capsulotomy permitted, more than 3 month prior to enrollment in the study eye
• Current or planned use of medications known to be toxic to the retina, lens or optic nerve (e.g. desferoximine, chloroquine/hydrochloroquine, chlorpromazine, phenothiazines, tamoxifen, nicotinic acid, and ethambutol)
• Significant disease or other medical conditions (as determined by medical history, examination and clinical investigations at screening) that may, in the opinion of the

investigator result in the any of the following:

• Put the patient at risk because of participation in the study
• Influence the results of the study,
• Cause concern regarding the patient's ability to participate in the study, e.g. cardiac (including tachycardia), gastro-intestinal, hepatic, renal, metabolic, dermatologic, neurological, haematological, oncological and psychiatric.
• Patients with malignancy for which the patient has undergone resection, radiation or chemotherapy within past 5 years. Patients with treated basal cell carcinoma or fully cured squamous cell carcinoma are allowed.
• Known hypersensitivity to any of the ingredients used in the Investigational Medical Product (IMP) formulation, or any of the medications used
• Active intraocular inflammation in the study eye
• Active infectious conjunctivitis in either eye
• Further exclusion criteria apply

Related Conditions & MeSH terms

• Atrophy
• Geographic Atrophy
• Macular Degeneration

Intervention

Drug:
• BI 754132
One single injection

Locations

Country	Name	City	State
United Kingdom	Bristol Eye Hospital	Bristol
United Kingdom	Royal Liverpool University Hospital	Liverpool
United Kingdom	Moorfields Eye Hospital	London
United Kingdom	Royal Victoria Infirmary	Newcastle upon Tyne
United Kingdom	Southampton General Hospital	Southampton
United States	Western Carolina Retinal Associate PA	Asheville	North Carolina
United States	Southeast Retina Center, PC	Augusta	Georgia
United States	Retina Consultants of Texas	Bellaire	Texas
United States	Retina-Vitreous Associates Medical Group	Beverly Hills	California
United States	Retina Foundation of the Southwest	Dallas	Texas
United States	Retina Specialty Institute	Pensacola	Florida
United States	Mid Atlantic Retina	Philadelphia	Pennsylvania
United States	Center for Retina and Macular Disease	Winter Haven	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SRD Part: Number of Patients With Ocular (in the Study Eye) or Systemic Dose Limiting Events (DLEs)	SRD part: Number of patients with ocular or systemic DLEs from drug administration. Systemic DLEs were defined as drug-related adverse events (AEs), as defined by the investigator, of moderate or severe intensity on the Common terminology criteria for adverse events (CTCAE) scale, and included diarrhea, cough, or patient-reported paraesthesia, dysgeusia, taste abnormality, taste disorder, or hyposmia. Single rising dose (SRD) part.	From drug administration until end of trial, up to 100 days.
Primary	MD Part: Number of Patients With Drug Related Adverse Events (AEs)	Number of patients with drug-related adverse events (AEs). Multiple dose (MD) part.	From drug administration until end of trial, up to 155 days
Secondary	SRD Part: Number of Patients With Drug-related Adverse Events (AEs)	Number of patients with drug-related AEs. Single rising dose (SRD) part.	From drug administration until end of trial, up to 100 days.
Secondary	SRD Part: Number of Patients With Any Ocular Adverse Events (AEs) in the Study Eye	Number of patients with any ocular adverse events in the study eye. Single rising dose (SRD) part.	From drug administration until end of trial, up to 100 days.
Secondary	SRD Part: Maximum Serum Concentration of BI 754132 After a Single Intravitreal Dose (Cmax)	Maximum serum concentration of BI 754132 after a single intravitreal dose (Cmax). Single rising dose (SRD) part.	At Day 1, 4, 8, 15, 29, 56, 84 and Day 100.
Secondary	SRD Part: Area Under the Concentration-time Curve of BI 754132 in Serum Over the Time Interval From 0 Extrapolated to Infinity (AUC0-8)	Area under the concentration-time curve of BI 754132 in serum over the time interval from 0 extrapolated to infinity (AUC0-8). Singe rising dose (SRD) part.	At Day 1, 4, 8, 15, 29, 56, 84 and Day 100.
Secondary	SRD Part: Time From Dosing to Maximum Serum Concentration of BI 754132 (Tmax)	Time from dosing to maximum serum concentration of BI 754132 (tmax). Single rising dose (SRD part).	At Day 1, 4, 8, 15, 29, 56, 84 and Day 100.
Secondary	MD Part: Trough Levels of BI 754132 Before Second Administration (Cmin,1)	Systematic exposure of BI 754132 after multiple intravitreal doses as assessed by Cmin,1 (trough levels of BI 754132 before second administration). Multiple dose (MD) part.	Up to 29 days.
Secondary	MD Part: Trough Levels of BI 754132 Before Third Administration (Cmin,2)	Systematic exposure of BI 754132 after multiple intravitreal doses as assessed by Cmin,2 (trough levels of BI 754132 before third administration). Multiple dose (MD) part.	Up to 57 days.
Secondary	MD Part: Plasma Concentration of BI 754132 4, 8 and 14 Weeks After the Third Administration	Plasma concentration of BI 754132 4, 8 and 14 weeks after the third administration. Multiple dose (MD) part.	At Day 85, 113 and Day 155.

External Links

•   Related Info